FXR Protein (Farnesoid X Receptor)
Overview <table class="infobox infobox-protein">
...
FXR Protein (Farnesoid X Receptor)
Overview <table class="infobox infobox-protein">
FXR (Farnesoid X Receptor, also known as NR1H4) is a nuclear receptor that functions as the primary sensor of bile acids in the body[@makishima1999]. FXR regulates bile acid synthesis, transport, and metabolism, while also playing important roles in glucose homeostasis, lipid metabolism, and inflammatory responses[@parks1999]. In the central nervous system, FXR is expressed in [neurons](/entities/neurons) and glial cells, where it modulates neuroinflammation, cholesterol metabolism, and synaptic plasticity—making it a potential therapeutic target for neurodegenerative diseases[@huang2016].
Protein Structure FXR has the characteristic nuclear receptor domain architecture with several isoforms:
Domain Architecture FXR Protein Structure
DBD: Two C4-type zinc fingers
AF-1 Domain : N-terminal activation function, isoform-specificDNA-binding Domain : Two zinc fingers for direct repeat-1 (DR-1) response elementsHinge Region : Flexible linker for conformational changesLigand-binding Domain : Binds primary bile acids (CDCA > DCA > CA > UDCA)AF-2 Helix : Completes the transcriptionally active conformationNormal Biological Function
FXR is the master regulator of bile acid homeostasis:
Bile Acid Synthesis Feedback :Activates CYP7A1 repression via FGF19 signaling
Inhibits bile acid synthesis when levels are high
Coordinates hepatic and intestinal signaling
Bile Acid Transport :Regulates BSEP (bile salt export pump)
Controls NTCP (sodium taurocholate cotransporter)
Modulates OSTα/β (organic solute transporter)
Enterohepatic Circulation :FGF19/15 signaling from intestine to liver
Coordinated regulation of bile acid pool
Glucose Homeostasis:
Enhances insulin sensitivity
Suppresses gluconeogenesis
Improves β-cell function
Lipid Metabolism:
Inhibits de novo lipogenesis
Reduces triglycerides
Modulates VLDL secretion
Anti-inflammatory Effects:
Inhibits [NF-κB](/entities/nf-kb) transcription
Reduces inflammatory cytokines
Protects against metabolic inflammation
Role in Neurodegeneration
Alzheimer's Disease FXR has emerged as a significant player in AD pathogenesis:
Cholesterol Metabolism:
FXR regulates cholesterol metabolism in the brain
Alters [APOE](/proteins/apoe) expression and lipidation
Affects [amyloid precursor protein](/entities/app-protein) processing
Neuroprotection:
FXR agonists reduce amyloid-β toxicity in models[@zhang2019]
Improves synaptic plasticity and memory
Reduces oxidative stress
Neuroinflammation:
Suppresses microglial activation
Reduces inflammatory cytokine expression
Protects against neuroinflammation
Therapeutic Potential:
FXR agonists in clinical development for AD
Combination approaches with other targets
Gene expression modulators
Parkinson's Disease FXR provides neuroprotection in PD models:
Dopaminergic Neurons:
Protects against 6-OHDA toxicity
Reduces mitochondrial dysfunction
Enhances neuronal survival
Neuroinflammation:
Modulates glial cell activation
Suppresses inflammatory responses
Reduces dopaminergic neuron loss
Potential Therapeutics:
FXR agonists show promise in preclinical studies
Obeticholic acid (OCA) being investigated
Cholesterol-lowering effects beneficial
Amyotrophic Lateral Sclerosis
Lipid metabolism modulation
Anti-inflammatory effects
Motor neuron protection
Multiple Sclerosis
Myelin lipid regulation
Anti-inflammatory properties
Demyelination protection
Genetic Associations
Protein Interactions
Transcriptional Complexes
Target Genes
Bile Acid Metabolism : CYP7A1, BSEP, NTCP, OSTα/βLipid Metabolism : ApoC-II, ApoC-III, PLTPGlucose Metabolism : PEPCK, G6PaseTransport : OSTα, OSTβ, MRP3Expression Patterns in the Brain
Cellular Distribution
Neurons : High expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum[Astrocytes](/entities/astrocytes) : Moderate expression[Microglia](/cell-types/microglia-neuroinflammation) : Lower expression, increases with activationOligodendrocytes : Present but lower levelsRegional Expression
Highest in cerebral cortex and hippocampus
Moderate in basal ganglia
Lower in brainstem
Regulation
Bile Acid Levels : Ligand-dependent activationInflammatory Signals : Suppressed by NF-κBMetabolic State : Regulated by nutritional statusTherapeutic Implications
FXR Agonists
Obeticholic Acid (OCA) : Semi-synthetic bile acidFDA-approved for PBC
Being studied for NASH and AD
Good safety profile
GW4064 : Synthetic FXR agonistResearch compound
High potency
Poor brain penetration
Cilofexor (GS-9674) : Non-bile acid FXR agonistImproved safety profile
Being studied for metabolic diseases
Challenges
Peripheral Effects : Liver and gastrointestinal actionsBrain Penetration : Limited for CNS applicationsPruritus : Side effect of potent agonistsAlternative Approaches
FGF19 Analogs : Target CNS expressionGene Therapy : Tissue-specific modulationSmall Molecule Modulators : Selective CNS effects[Bile Acid Metabolism](/mechanisms/bile-acid-metabolism)
[Cholesterol Metabolism](/data/pages/cerebral_cholesterol_metabolism)
[NF-κB Signaling](/mechanisms/nf-kb-signaling-neuroinflammation)
[FGF Signaling](/mechanisms/fgf-signaling-pathway)
[Neuroinflammation](/mechanisms/neuroinflammation)
[NR1H4 Gene (FXRα)](/genes/nr1h4)
[SHP (NR0B2) Gene](/genes/nr0b2)
[RXRα Protein](/proteins/rxra-protein)
[FGF19 Protein](/proteins/fgf19-protein)
[APOE Protein](/proteins/apoe-protein)
See Also
[Bile Acid Metabolism](/mechanisms/bile-acid-metabolism)
[NF-κB Signaling](/mechanisms/nf-kb-signaling-neuroinflammation)
[FGF Signaling](/mechanisms/fgf-signaling-pathway)
[Neuroinflammation](/mechanisms/neuroinflammation)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Makishima et al., Identification of FXR as bile acid receptor (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10541541/)
[Parks et al., FXR regulates cholesterol homeostasis (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10541542/)
[Huang et al., FXR in brain function (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27013187/)
[Zhang et al., FXR agonists in AD models (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31154989/)
[Mertens et al., FXR and neuroinflammation (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28521052/) Show full description